{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:53:12Z","timestamp":1780721592350,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","interventional.theclinics.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.iccl.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T12:08:33Z","timestamp":1723032513000},"page":"493-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antithrombotic Therapy in Patients with Chronic Coronary Syndromes"],"prefix":"10.1016","volume":"13","author":[{"given":"Placido Maria","family":"Mazzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iccl.2024.06.004_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/hrt.50.2.127","article-title":"Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi","volume":"50","author":"Falk","year":"1983","journal-title":"Br Heart J"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.004_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Writing Committee","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.iccl.2024.06.004_bib3","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.004_bib4","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.iccl.2024.06.004_bib5","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","article-title":"Antithrombotic therapy after transcatheter aortic valve replacement","volume":"14","author":"Capodanno","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.004_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.004_bib7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease","volume":"82","author":"Virani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9678","key":"10.1016\/j.iccl.2024.06.004_bib8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.iccl.2024.06.004_bib9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMoa2200963","article-title":"CT or invasive coronary angiography in stable chest pain","volume":"386","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9038","key":"10.1016\/j.iccl.2024.06.004_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.004_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.iccl.2024.06.004_bib13","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.004_bib14","doi-asserted-by":"crossref","first-page":"e024156","DOI":"10.1161\/JAHA.121.024156","article-title":"ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI Trial","volume":"11","author":"Capodanno","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.004_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.004_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/14779072.2022.2137492","article-title":"Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk","volume":"20","author":"Mazzone","year":"2022","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.004_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/bcp.14317","article-title":"Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis","volume":"86","author":"Yoon","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.004_bib18","first-page":"1112","article-title":"High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials","volume":"47","author":"Sheng","year":"2022","journal-title":"J\u00a0Clin Pharm Therapeut"},{"key":"10.1016\/j.iccl.2024.06.004_bib19","doi-asserted-by":"crossref","first-page":"994184","DOI":"10.3389\/fcvm.2022.994184","article-title":"CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel","volume":"9","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.004_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/pgs-2021-0098","article-title":"Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis","volume":"23","author":"Biswas","year":"2022","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.004_bib21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10557-021-07142-w","article-title":"Association of CYP2C19 loss-of-function alleles with major adverse cardiovascular events of clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention: meta-analysis","volume":"35","author":"Biswas","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.004_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/FJC.0000000000001164","article-title":"Clinical outcomes after percutaneous coronary intervention over time on the basis of CYP2C19 polymorphisms","volume":"79","author":"Zhang","year":"2022","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"26","key":"10.1016\/j.iccl.2024.06.004_bib23","doi-asserted-by":"crossref","first-page":"e4049","DOI":"10.1097\/MD.0000000000004049","article-title":"CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents","volume":"95","author":"Choi","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.004_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40256-022-00565-2","article-title":"CYP2C9 polymorphisms and the risk of cardiovascular events in patients treated with clopidogrel: combined data from the popular genetics and popular AGE trials","volume":"23","author":"van den Broek","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10235","key":"10.1016\/j.iccl.2024.06.004_bib25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.004_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.004_bib27","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.004_bib28","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after pci in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.iccl.2024.06.004_bib29","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.004_bib30","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.004_bib31","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.004_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2017.11.050","article-title":"Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease","volume":"71","author":"Bansilal","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.004_bib33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.004_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11239-023-02821-x","article-title":"Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease","volume":"56","author":"Mazzone","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.004_bib35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.004_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2024.06.004_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ahj.2023.08.001","article-title":"Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI","volume":"265","author":"Piccolo","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2024.06.004_bib39","article-title":"ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"Joglar","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2024.06.004_bib40","doi-asserted-by":"crossref","first-page":"e05","DOI":"10.15420\/icr.2021.30","article-title":"Antithrombotic management in af patients following percutaneous coronary intervention: a European perspective","volume":"18","author":"Greco","year":"2023","journal-title":"Intervent Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.004_bib41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.004_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.iccl.2024.06.004_bib43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.004_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10293","key":"10.1016\/j.iccl.2024.06.004_bib45","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.004_bib46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.004_bib47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.004_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17434440.2022.2106853","article-title":"Antithrombotic therapy after transcatheter aortic valve implantation","volume":"19","author":"Greco","year":"2022","journal-title":"Expet Rev Med Dev"},{"issue":"15","key":"10.1016\/j.iccl.2024.06.004_bib49","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.004_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib51","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.004_bib52","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.004_bib53","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.004_bib54","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.004_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"4\u20135","key":"10.1016\/j.iccl.2024.06.004_bib56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.pcad.2017.12.004","article-title":"Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy","volume":"60","author":"Moon","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"15","key":"10.1016\/j.iccl.2024.06.004_bib57","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.004_bib58","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.004_bib59","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12928-015-0366-9","volume":"31","author":"Natsuaki","year":"2016","journal-title":"Cardiovasc Interv Ther"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.004_bib60","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.123.064264","article-title":"Comparison of 3- to 6-Month Versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: The HOST-IDEA Randomized Clinical Trial","volume":"147","author":"Han","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib61","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.004_bib62","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after pci in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.iccl.2024.06.004_bib63","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"10151","key":"10.1016\/j.iccl.2024.06.004_bib64","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.iccl.2024.06.004_bib65","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.iccl.2024.06.004_bib66","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.004_bib67","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.004_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCULATIONAHA.122.062762","article-title":"Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, end point\u2013blinded, noninferiority trial","volume":"147","author":"Wu","year":"2023","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.004_bib69","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jcin.2021.07.045","article-title":"Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights from the AFIRE trial","volume":"14","author":"Matoba","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.004_bib70","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib71","doi-asserted-by":"crossref","first-page":"e017212","DOI":"10.1161\/JAHA.120.017212","article-title":"Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.iccl.2024.06.004_bib72","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib73","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.004_bib74","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10206","key":"10.1016\/j.iccl.2024.06.004_bib75","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.004_bib76","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.004_bib77","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.004_bib78","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.004_bib79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.iccl.2024.06.004_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2023.2291865","article-title":"Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management","author":"Laudani","year":"2023","journal-title":"Expet Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.004_bib81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.004_bib82","doi-asserted-by":"crossref","first-page":"e008349","DOI":"10.1161\/CIRCINTERVENTIONS.119.008349","article-title":"Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial","volume":"13","author":"Berry","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.004_bib83","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2017.11.009","article-title":"Effect of procedure and coronary lesion characteristics on clinical outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial","volume":"11","author":"Kerneis","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"47","key":"10.1016\/j.iccl.2024.06.004_bib84","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1093\/eurheartj\/ehaa617","article-title":"Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial","volume":"41","author":"Vranckx","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T22:55:43Z","timestamp":1725836143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745824000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2211745824000634"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.004","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy in Patients with Chronic Coronary Syndromes","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}